Delayed Trastuzumab-induced Cardiotoxicity Leading to Severe Left Ventricular Dysfunction

被引：0

作者：

Misumi, Ikuo ^{[1
]}

Nishimura, Reiki ^{[2
]}

Nakamura, Shota ^{[3
]}

Sato, Koji ^{[4
]}

Dekita, Miwa ^{[4
]}

Usuku, Hiroki ^{[5
]}

Tsujita, Kenichi ^{[5
]}

机构：

[1] Ueki Hosp, Dept Cardiol, Kumamoto, Japan

[2] Kumamoto Brest & Gastrointestinal Surg Hosp, Dept Surg, Kumamoto, Japan, Japan

[3] Kumamoto Shinto Gen Hosp, Dept Cardiol, Kumamoto, Japan

[4] Kumamoto City Hosp, Dept Cardiol, Kumamoto, Japan

[5] Kumamoto Univ, Sch Med, Dept Cardiovasc Med, Kumamoto, Japan

来源：

INTERNAL MEDICINE | 2024年

关键词：

Delayed trastuzumab-induced cardiotoxicity; Septal injury; Cardiac magnetic resonance;

D O I：

10.2169/internalmedicine.4144-24

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

An 81-year-old woman presented to our hospital with dyspnea. She had been treated with trastuzumab for nine years. Chest radiography revealed pleural effusion. Transthoracic echocardiography revealed dyskinesis of the interventricular septum (IVS). Cardiac magnetic resonance imaging revealed increased native T1 values at the interventricular septum and apex, indicating myocardial edema or fibrosis in these areas. A transthoracic echocardiogram after half a year revealed an increase in LVEF from 25% to 48%. Serial transthoracic echocardiography and cardiac magnetic resonance imaging were useful for evaluating the cardiac structure and function in the present case of delayed trastuzumab-induced myocardial injury.

引用

页数：9

共 50 条

[1] Cardiac autonomic modulation with donepezil attenuates pyroptosis and mitochondrial dysfunction, leading to improved left ventricular function in trastuzumab-induced cardiotoxicity in rats
Khuanjing, T.
Maneechote, C.
Ongnok, B.
Prathumsap, N.
Arinno, A.
Chunchai, T.
Arunsak, B.
Chattipakorn, S. C.
Chattipakorn, N.
EUROPEAN HEART JOURNAL, 2022, 43 : 2570 - 2570
[2] Trastuzumab-Induced Cardiotoxicity
Stegall, Lisa
Starbuck, Mandy Fields
Mayer, Deborah K.
Harwood, Elaine Brooks
Glotzer, Jana
ONCOLOGY NURSING FORUM, 2009, 36 (06) : 676 - 685
[3] Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge
Tocchetti, Carlo G.
Ragone, Gianluca
Coppola, Carmela
Rea, Domenica
Piscopo, Giovanna
Scala, Stefania
De Lorenzo, Claudia
Iaffaioli, Rosario V.
Arra, Claudio
Maurea, Nicola
EUROPEAN JOURNAL OF HEART FAILURE, 2012, 14 (02) : 130 - 137
[4] Trastuzumab-Induced Cardiotoxicity: Is it a Personalized Risk?
Milano, Gerard A.
Serres, Emilie
Ferrero, Jean-Marc
Ciccolini, Joseph
CURRENT DRUG TARGETS, 2014, 15 (13) : 1200 - 1204
[5] Trastuzumab-induced cardiac dysfunction
Panjrath, Gurusher Singh
Jain, Diwakar
NUCLEAR MEDICINE COMMUNICATIONS, 2007, 28 (02) : 69 - 73
[6] Trastuzumab-induced cardiotoxicity: Heart failure at the crossroads
Sengupta, Partho P.
Northfelt, Donald W.
Gentile, Federico
Zamorano, Jose L.
Khandheria, Bijoy K.
MAYO CLINIC PROCEEDINGS, 2008, 83 (02) : 197 - 203
[7] Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer
Nicolazzi, M. A.
Carnicelli, A.
Fuorlo, M.
Scaldaferri, A.
Masetti, R.
Landolfi, R.
Favuzzi, A. M. R.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2018, 22 (07) : 2175 - 2185
[8] Protective strategies to prevent trastuzumab-induced cardiotoxicity
Guo, Shaohua
Tse, Gary
Liu, Tong
LANCET, 2020, 395 (10223): : 491 - 492
[9] Intermittent left bundle branch block and acute heart failure in trastuzumab-induced cardiotoxicity
Masson, Ravi
Bakhshi, Hooman
Haddad, Tariq M.
BMJ CASE REPORTS, 2020, 13 (07)
[10] Anthracycline- and trastuzumab-induced cardiotoxicity: a retrospective study
Yasmin Hamirani
Ibrahim Fanous
Christopher M. Kramer
Andrew Wong
Michael Salerno
Patrick Dillon
Medical Oncology, 2016, 33

← 1 2 3 4 5 →